Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase 1 33Phase 1/2 17Phase 3 5Phase NA 1Phase EARLY_PHASE1 1

Status

Active not recruiting 3Terminated 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Breast 1

Conditions

Ovarian Neoplasms 2mCRPC 1Prostatic Neoplasms 1Fallopian Tube Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × talazoparib × Clear all
NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer

Phase 3 Active not recruiting
599 enrolled
Genitourinary

Prostatic Neoplasms

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Pfizer

Phase 3 Terminated
79 enrolled 18 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01945775 2022-01-20

EMBRACA

Pfizer

Phase 3 Completed
431 enrolled 23 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡